| Assessment Status | Assessment process complete |
| HTA ID | 21042 |
| Drug | Hydrocortisone modified-release hard capsules |
| Brand | Efmody® |
| Indication | For the treatment of congenital adrenal hyperplasia in adolescents aged 12 years and over and adults. |
| Assessment Process | |
| Rapid review commissioned | 08/09/2021 |
| Rapid review completed | 04/11/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Efmody® not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
